State of New Jersey Common Pension Fund D’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-289,978
Closed -$2.84M 1581
2023
Q4
$2.84M Buy
289,978
+67,107
+30% +$549K 0.01% 1164
2023
Q3
$1.86M Buy
222,871
+29,347
+15% +$335K 0.01% 1546
2023
Q2
$2.57M Sell
193,524
-55,564
-22% -$675K 0.01% 1240
2023
Q1
$2.88M Buy
249,088
+24,034
+11% +$239K 0.01% 890
2022
Q4
$1.84M Buy
+225,054
New +$1.94M 0.01% 1587
2022
Q2
Sell
-244,882
Closed -$2.23M 1752
2022
Q1
$2.23M Buy
244,882
+129,084
+111% +$1.49M 0.01% 1573
2021
Q4
$2.37M Sell
115,798
-2,236
-2% -$54K 0.01% 1612
2021
Q3
$3.02M Buy
118,034
+1,283
+1% +$38K 0.01% 1064
2021
Q2
$4.08M Buy
116,751
+8,398
+8% +$244K 0.01% 841
2021
Q1
$3.61M Sell
108,353
-34,707
-24% -$1.21M 0.01% 925
2020
Q4
$3.71M Buy
+143,060
New +$2.43M 0.01% 883

Other funds holding PACB

State of New Jersey Common Pension Fund D's PACB Position: Q1 2024 in Review

State of New Jersey Common Pension Fund D sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 289,978 shares — an estimated $2.84M sold.

State of New Jersey Common Pension Fund D first reported a position in PACB in Q4 2020 and held it in 11 quarters. The position peaked at $4.08M in Q2 2021. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

  • State of New Jersey Common Pension Fund D reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
  • State of New Jersey Common Pension Fund D sold 289,978 Pacific Biosciences shares in Q1 2024, an estimated $2.84M.
  • State of New Jersey Common Pension Fund D first reported a position in Pacific Biosciences in Q4 2020 and held it in 11 quarters.
  • State of New Jersey Common Pension Fund D's Pacific Biosciences position peaked at $4.08M in Q2 2021.
  • 268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on State of New Jersey Common Pension Fund D's 13F filing for Q1 2024, filed 2 May 2024.